FDA Issued Emergency Use Authorization for Point of Care Ant
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for a COVID-19 antigen diagnostic test, the BD (Becton Dickinson) Veritor System for Rapid Detection of SARS-CoV-2.

• Second antigen test the FDA has authorized for the detection of SARS-CoV-2 antigens

• It can be administered at the point of care and produce results within 15 minutes,

• FDA has touted the tests as an important tool for combating the pandemic because they can be produced quickly, at relatively low costs, and test patients in a variety of settings.

• Becton Dickinson’s test can be used on its existing BD Veritor System platform.

• The platform is slightly larger than a cellphone and does not need to be operated by specialized laboratory scientists, the company said.

• Becton Dickinson said it would be able to produce 2 million tests a week by the end of September.

Source: https://www.cnbc.com/2020/07/06/us-regulator-greenlights-becton-dickinsons-rapid-antigen-test-for-coronavirus.html
Dr. I●●●●●●E G●●●A and 6 others like this2 shares
Like
Comment
Share